{"protocolSection": {"identificationModule": {"nctId": "NCT05920356", "orgStudyIdInfo": {"id": "20190341"}, "secondaryIdInfos": [{"id": "2022-501863-41", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Amgen", "class": "INDUSTRY"}, "briefTitle": "A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)", "officialTitle": "A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)"}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Amgen", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy."}, "conditionsModule": {"conditions": ["Non-Small Cell Lung Cancer (NSCLC)"], "keywords": ["Oncology", "Lung Cancer", "PD-L1", "KRAS p.G12C", "Sotorasib", "Pembrolizumab", "Carboplatin", "Pemetrexed", "CodeBreaK 202", "NSCLC", "PD-L1 Negative", "AMG 510", "LUMAKRAS \u00ae", "LUMYKRAS \u00ae"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 750, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sotorasib combined with carboplatin and pemetrexed", "type": "EXPERIMENTAL", "description": "Sotorasib administered in combination with carboplatin and pemetrexed.", "interventionNames": ["Drug: Sotorasib"]}, {"label": "Pembrolizumab combined with carboplatin and pemetrexed", "type": "ACTIVE_COMPARATOR", "description": "Pembrolizumab administered in combination with carboplatin and pemetrexed.", "interventionNames": ["Drug: Pembrolizumab"]}], "interventions": [{"type": "DRUG", "name": "Sotorasib", "description": "Oral administration", "armGroupLabels": ["Sotorasib combined with carboplatin and pemetrexed"], "otherNames": ["AMG 510", "LUMYKRAS \u00ae", "LUMAKRAS \u00ae"]}, {"type": "DRUG", "name": "Pembrolizumab", "description": "Intravenous administration", "armGroupLabels": ["Pembrolizumab combined with carboplatin and pemetrexed"]}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of nonsquamous stage IV or advanced Stage IIIB or IIIC NSCLC with KRAS p. G12C mutation and negative for PD-L1 expression by central testing or local laboratory testing confirmed through central testing\n* No history of systemic anticancer therapy in metastatic/non-curable settings\n* Eastern Cooperative Oncology Group (ECOG) \u2264 1\n\nExclusion Criteria:\n\n* Mixed histology NSCLC with either small-cell or large-cell neuroendocrine cell component or predominant squamous cell histology\n* Participants with tumors known to harbor molecular alterations for which targeted therapy is locally approved\n* Symptomatic (treated or untreated) brain metastases\n* Gastrointestinal (GI) tract disease causing the inability to take oral medication\n* Myocardial infarction within 6 months of randomization, unstable arrhythmias, or unstable angina\n* Prior therapy with a KRAS G12C inhibitor", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "100 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Amgen Call Center", "role": "CONTACT", "phone": "866-572-6436", "email": "medinfo@amgen.com"}], "overallOfficials": [{"name": "MD", "affiliation": "Amgen", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"seeAlsoLinks": [{"label": "AmgenTrials clinical trials website", "url": "http://www.amgentrials.com"}]}}, "hasResults": false}